Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,313 · see citing works

A quantitative analysis of kinase inhibitor selectivity

Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466 · see citing works

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013 · see citing works

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 950 · see citing works

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865 · see citing works

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730 · see citing works

Epidermal Growth Factor Receptor Targeting in Cancer

Mendelsohn, J. M., & Baselga, J. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693 · see citing works

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0314 · Cited by 620 · see citing works

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 550 · see citing works

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

Fry, D. W., Bridges, A. J., Denny, W. A., Doherty, A. M., Greis, K. D., Hicks, J. L., Hook, K. E., Keller, P. R., Leopold, W. R., Loo, J. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.12022 · Cited by 424 · see citing works

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Flanagan, M., Blumenkopf, T., Brissette, W., Brown, M. F., Casavant, J. M., Chang, S.-P., Doty, J. L., Elliott, E., Fisher, M., Hines, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1004286 · Cited by 334 · see citing works

Tyrosine Kinase Inhibitors. 8. An Unusually Steep Structure−Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor

Bridges, A. J., Zhou, H., Cody, D. R., Rewcastle, G. W., McMichael, A., Showalter, H. D. H., Fry, D. W., Kraker, A. J., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9503613 · Cited by 320 · see citing works

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

Janne, P. A., Gray, N. S., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303 · see citing works

Integration of EGFR inhibitors with radiochemotherapy

Nyati, M. K., Morgan, M. A., Feng, F. Y.-C., & Lawrence, T. S. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1953 · Cited by 302 · see citing works

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity

Tsou, H., Overbeek, E., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C. M., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 302 · see citing works

Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N. N., Rosfjord, E. C., Discafani, C. M., Davis, R. E., Shi, X., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 270 · see citing works

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., Lipka, E., Showalter, H. D. H., Vincent, P. W., Elliott, W. L., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990482t · Cited by 269 · see citing works

6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity

Tsou, H., Mamuya, N. N., Johnson, B. D., Reich, M. F., Gruber, B. C., Ye, F., Nilakantan, R., Shen, R., Discafani, C. M., DeBlanc, R., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0005555 · Cited by 269 · see citing works

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Ramalingam, S. S., Blackhall, F. H., Krzakowski, M. J., Barrios, C. H., Park, K., Bover, I., Heo, D. S., Rosell, R., Talbot, D. C., Frank, R. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9433 · Cited by 263 · see citing works

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226 · see citing works

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220 · see citing works

Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition

Gajiwala, K. S., Feng, J., Ferre, R. A., Ryan, K., Brodsky, O., Weinrich, S. L., Kath, J. C., & Stewart, A. (2012) · Structure · doi:10.1016/j.str.2012.11.014 · Cited by 204 · see citing works

The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

Kim, Y.-W., Ko, J., Cui, Z.-Y., Abolhoda, A., Ahn, J. S., Ou, S.-H., Ahn, M., & Park, K. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0750 · Cited by 179 · see citing works

Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyrido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor

Smaill, J. B., Palmer, B. D., Rewcastle, G. W., Denny, W. A., McNamara, D. J., Dobrusin, E. M., Bridges, A. J., Zhou, H., Showalter, H. D. H., Winters, R. T., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806603 · Cited by 176 · see citing works

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Petrov, K. G., Zhang, Y.-M., Carter, M., Cockerill, G. S., Dickerson, S. H., Gauthier, C., Guo, Y. C., Mook, R. A., Rusnak, D. W., Walker, A. L., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.05.090 · Cited by 168 · see citing works

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)

Reid, A. H. M., Vidal, L., Shaw, H. M., & Bono, J. S. D. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.11.007 · Cited by 155 · see citing works

Current approaches and future directions in the treatment of HER2-positive breast cancer

Hurvitz, S. A., Hu, Y., O’Brien, N. A., & Finn, R. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.008 · Cited by 151 · see citing works

Tyrosine Kinase Inhibitors. 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor

Rewcastle, G. W., Palmer, B. D., Bridges, A. J., Showalter, H. D. H., Sun, L., Nelson, J. M., McMichael, A., Kraker, A. J., Fry, D. W., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950692f · Cited by 150 · see citing works

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Erlichman, C., Hidalgo, M. M., Boni, J. P., Martins, P., Quinn, S., Zacharchuk, C., Amorusi, P., Adjei, A. A., & Rowinsky, E. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8960 · Cited by 149 · see citing works

Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes

Nunes, M., Shi, C., & Greenberger, L. M. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.21.3.1 · Cited by 145 · see citing works

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Ramalingam, S. S., Janne, P. A., Mok, T. S. K., O'Byrne, K. J., Boyer, M. J., von Pawel, J., Płużański, A., Shtivelband, M. I., Docampo, L. I., Bennouna, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70452-8 · Cited by 140 · see citing works

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Ellis, P. M., Shepherd, F. A., Millward, M. J., Perrone, F., Seymour, L., Liu, G., Sun, S. B., Cho, B. C., Morabito, A., Leighl, N. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70472-3 · Cited by 132 · see citing works

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Jänne, P. A., Ou, S.-H. I., Kim, D.-W., Oxnard, G. R., Martins, R., Kris, M. G., Dunphy, F., Nishio, M., O'Connell, J., Paweletz, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70461-9 · Cited by 127 · see citing works

Where next for gefitinib in patients with lung cancer?

Blackhall, F. H., Ranson, M., & Thatcher, N. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70725-2 · Cited by 123 · see citing works

Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]- pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor

Rewcastle, G. W., Palmer, B. D., Thompson, A. M., Bridges, A. J., Cody, D. R., Zhou, H., Fry, D. W., McMichael, A., & Denny, W. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9508651 · Cited by 114 · see citing works

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Wood, E. R., Shewchuk, L. M., Ellis, B., Brignola, P. S., Brashear, R. L., Caferro, T. R., Dickerson, S. H., Dickson, H. D., Donaldson, K. H., Gaul, M. D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708281105 · Cited by 113 · see citing works

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with In Vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)

Discafani, C. M., Carroll, M. L., Floyd, M. B., Hollander, I. J., Husain, Z., Johnson, B. D., Kitchen, D., May, M. K., Malo, M. S., Minnick, A. A., et al. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00356-6 · Cited by 112 · see citing works

Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency

Wu, C.-H., Coumar, M. S., Chu, C.-Y., Lin, W., Chen, Y., Chen, C.-T., Shiao, H., Rafi, S., Wang, S.-Y., Hsu, H., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100607r · Cited by 110 · see citing works

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer

Campos, S. M., Hamid, O., Seiden, M. V., Oza, A. M., Plante, M., Potkul, R. K., Lenehan, P. F., Kaldjian, E. P., Varterasian, M. L., Jordan, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.091 · Cited by 106 · see citing works

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Razak, A. R. A., Soulières, D., Laurie, S. A., Hotte, S. J., Singh, S., Winquist, E., Chia, S., Tourneau, C. L., Nguyen‐Tan, P. F., Chen, E. X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds503 · Cited by 104 · see citing works

CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer

Allen, L. F. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.009 · Cited by 99 · see citing works

Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor

Lackey, K. E. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743156 · Cited by 92 · see citing works

Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

Smaill, J. B., Showalter, H. D. H., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., Nelson, J. M., Sherwood, V., Vincent, P. W., Roberts, B. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000372i · Cited by 89 · see citing works

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Kalous, O., Conklin, D. F., Desai, A. J., O’Brien, N. A., Ginther, C., Anderson, L. A., Cohen, D. J., Britten, C. D., Taylor, I. W., Christensen, J. G., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0730 · Cited by 86 · see citing works

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Nemunaitis, J. J., Eiseman, I. A., Cunningham, C. C., Senzer, N. N., Williams, A., Lenehan, P. F., Olson, S. C., Bycott, P. W., Schlicht, M., Zentgraff, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1950 · Cited by 86 · see citing works

Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain

Cohen, B. D., Goldstein, D. J., Rutledge, L., Vass, W. C., Lowy, D. R., Schlegel, R., & Schiller, J. T. (1993) · Journal of Virology · doi:10.1128/jvi.67.9.5303-5311.1993 · Cited by 82 · see citing works

Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors

Klutchko, S. R., Zhou, H., Winters, R. T., Tran, T. P., Bridges, A. J., Althaus, I. W., Amato, D. M., Elliott, W. L., Ellis, P. A., Meade, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050936o · Cited by 81 · see citing works

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

Calvo, E., Tolcher, A. W., Hammond, L. A., Patnaik, A., Bono, J. S. D., Eiseman, I. A., Olson, S. C., Lenehan, P. F., McCreery, H., LoRusso, P. M., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1187 · Cited by 81 · see citing works

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Cockerill, S. G., Stubberfield, C. R., Stables, J. N., Carter, M., Guntrip, S. B., Smith, K., McKeown, S. C., Shaw, R., Topley, P., Thomsen, L. L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00219-0 · Cited by 80 · see citing works

Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

Nam, H.-J., Ching, K. A., Kan, J. L. C., Kim, H., Han, S., Im, S., Kim, T., Christensen, J. G., Oh, D., & Bang, Y. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0494 · Cited by 79 · see citing works

Mechanism of action of erbB tyrosine kinase inhibitors

Fry, D. W. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00095-2 · Cited by 78 · see citing works

Fast-Forwarding Hit to Lead: Aurora and Epidermal Growth Factor Receptor Kinase Inhibitor Lead Identification

Coumar, M. S., Chu, C., Lin, C., Shiao, H., Ho, Y.-L., Reddy, R., Lin, W., Chen, C.-H., Peng, Y., Leou, J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000198 · Cited by 71 · see citing works

Discovery of selective irreversible inhibitors for EGFR-T790M

Zhou, W., Ercan, D., Janne, P. A., & Gray, N. S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.036 · Cited by 67 · see citing works

Piperazine Imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABAALigands of Dual Functionality

Jacobsen, E. J., Stelzer, L. S., TenBrink, R. E., Belonga, K. L., Carter, D. B., Im, H. K., Im, W. B., Sethy, V. H., Tang, A. H., VonVoigtlander, P. F., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9801307 · Cited by 67 · see citing works

Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC

Janne, P. A., Schellens, J. H. M., Engelman, J. A., Eckhardt, S. G., Millham, R., Denis, L. J., Britten, C. D., Wong, S. G., Boss, D. S., & Camidge, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8027 · Cited by 67 · see citing works

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

Takahashi, T., Boku, N., Murakami, H., Naito, T., Tsuya, A., Nakamura, Y., Ono, A., Machida, N., Yamazaki, K., Watanabe, J., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9789-z · Cited by 64 · see citing works

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Gaul, M. D., Guo, Y. C., Affleck, K., Cockerill, G. S., Gilmer, T. M., Griffin, R., Guntrip, S. B., Keith, B. R., Knight, W. B., Mullin, R. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01047-8 · Cited by 58 · see citing works

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

Ramalingam, S. S., O'Byrne, K. J., Boyer, M. J., Mok, T. S. K., Janne, P. A., Zhang, H., Liang, J. J., Taylor, I. W., Sbar, E. I., & Paz-Ares, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv593 · Cited by 57 · see citing works

Irreversible kinase inhibitors gain traction

Sanderson, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4103 · Cited by 52 · see citing works

Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion

Carmi, C., Cavazzoni, A., Vezzosi, S., Bordi, F., Vacondio, F., Silva, C., Rivara, S., Lodola, A., Alfieri, R. R., Monica, S. L., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901558p · Cited by 51 · see citing works

Synthesis and SAR of potent EGFR/erbB2 dual inhibitors

Zhang, Y., Cockerill, S. G., Guntrip, S. B., Rusnak, D. W., Smith, K., Vanderwall, D. E., Wood, E. R., & Lackey, K. E. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.010 · Cited by 51 · see citing works

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

Brzezniak, C. E., Carter, C. A., & Giaccone, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758714 · Cited by 48 · see citing works

Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase

Hur, W., Velentza, A. V., Kim, S., Flatauer, L. J., Jiang, X., Valente, D., Mason, D. E., Suzuki, M., Larson, B., Zhang, J., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.062 · Cited by 41 · see citing works

First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.

Kris, M. G., Mok, T. S. K., Ou, S. I., Martins, R. G., Kim, D., Goldberg, Z., Zhang, H., Taylor, I. W., Letrent, S. P., & Janne, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7530 · Cited by 41 · see citing works

Discovery of A Novel Her-1/Her-2 Dual Tyrosine Kinase Inhibitor for the Treatment of Her-1 Selective Inhibitor-Resistant Non-small Cell Lung Cancer

Cha, M. Y., Lee, K., Kim, J. W., Lee, C. G., Song, J. Y., Kim, Y. H., Lee, G. S., Park, S. B., & Kim, M. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901146p · Cited by 37 · see citing works

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

Ather, F., Hamidi, H., Fejzo, M. S., Letrent, S. P., Finn, R. S., Kabbinavar, F. F., Head, C. S., & Wong, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056112 · Cited by 36 · see citing works

Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside

Tsang, R. Y., Sadeghi, S., & Finn, R. S. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s3783 · Cited by 35 · see citing works

Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer

Zinner, R., Nemunaitis, J. J., Eiseman, I. A., Shin, H. J. C., Olson, S. C., Christensen, J. G., Huang, X., Lenehan, P. F., Donato, N. J., & Shin, D. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1958 · Cited by 28 · see citing works

PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.

Park, K., Heo, D. S., Cho, B., Kim, D., Ahn, M.-J., Lee, S., Millham, R., Campbell, A., Zhang, H., & Kim, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.7599 · Cited by 23 · see citing works

Erlotinib: Optimizing Therapy with Predictors of Response?

Goodin, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0426 · Cited by 22 · see citing works

Breast cancer biology blossoms in the clinic

Nass, S. J., Hahm, H. A., & Davidson, N. E. (1998) · Nature Medicine · doi:10.1038/nm0798-761 · Cited by 18 · see citing works

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Nam, H.-J., Kim, H.-P., Yoon, Y., Song, S. H., Min, A.-R., Han, S., Im, S., Kim, T. Y., Oh, D. Y., & Bang, Y. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9782-6 · Cited by 17 · see citing works

Front-line therapy in lung cancer with mutations in EGFR

Landi, L. M., & Cappuzzo, F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.135 · Cited by 17 · see citing works

Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives.

Nomoto, Y., Obase, H., TAKAI, H., HIRATA, T., TERANISHI, M., Nakamura, J., & Kubo, K. (1990) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.38.1591 · Cited by 16 · see citing works

Dacomitinib for the Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer

Mok, T. S. K., Lee, K., Tang, M., & Leung, L. K. S. (2014) · Future Oncology · doi:10.2217/fon.14.22 · Cited by 10 · see citing works

EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC

Gorden, K. J., Mesbah, P., & Kolesar, J. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211408373 · Cited by 6 · see citing works

Properties of FDA-approved small molecule protein kinase inhibitors

Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554 · see citing works

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers

Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 495 · see citing works

Fluorine‐Containing Drugs Approved by the FDA in 2018

Mei, H., Han, J., Fustero, S., Medio‐Simón, M., Sedgwick, D. M., Santi, C., Ruzziconi, R., & Soloshonok, V. A. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901840 · Cited by 461 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

An overview of quinazolines: Pharmacological significance and recent developments

Alagarsamy, V., Chitra, K., Saravanan, G., Solomon, V. R., Sulthana, M. T., & Narendhar, B. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.076 · Cited by 278 · see citing works

DEEPScreen: high performance drug–target interaction prediction with convolutional neural networks using 2-D structural compound representations

Rifaioğlu, A. S., Nalbat, E., Atalay, V., Martin, M. J., Çetin-Atalay, R., & Doğan, T. (2020) · Chemical Science · doi:10.1039/c9sc03414e · Cited by 241 · see citing works

Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry

Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173 · see citing works

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Lu, X., Smaill, J. B., Patterson, A. V., & Ding, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01719 · Cited by 146 · see citing works

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors

Amelia, T., Kartasasmita, R. E., Ohwada, T., & Tjahjono, D. H. (2022) · Molecules · doi:10.3390/molecules27030819 · Cited by 142 · see citing works

A review: FDA-approved fluorine-containing small molecules from 2015 to 2022

Sheikhi, N., Bahraminejad, M., Saeedi, M., & Mirfazli, S. S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115758 · Cited by 141 · see citing works

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry

Das, D., & Hong, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.004 · Cited by 110 · see citing works

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97 · see citing works

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)

Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 90 · see citing works

Synthetic Approaches to New Drugs Approved During 2016

Flick, A. C., Ding, H. X., Leverett, C. A., Fink, S. J., & O’Donnell, C. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00260 · Cited by 70 · see citing works

Targeting Gatekeeper Mutations for Kinase Drug Discovery

Zhou, Y., Xiang, S., Yang, F., & Lu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01361 · Cited by 68 · see citing works

Synthetic Approaches to New Drugs Approved during 2018

Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Helal, C. J., DeForest, J. C., Morse, P., Mahapatra, S., & O’Donnell, C. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00345 · Cited by 66 · see citing works

Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease

Veale, C. G. L. (2019) · ChemMedChem · doi:10.1002/cmdc.201800755 · Cited by 60 · see citing works

Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)

Shen, J., Zhang, T., Zhu, S., Sun, M., Tong, L., Lai, M., Zhang, R., Xu, W., Wu, R., Ding, J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00576 · Cited by 57 · see citing works

A Review on Fused Pyrimidine Systems as EGFR Inhibitors and Their Structure–Activity Relationship

Yadav, T., Shaikh, G. M., Kumar, M. S., Chintamaneni, M., & Mayur, Y. C. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.861288 · Cited by 54 · see citing works

Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents

Abbas, N., Matada, G. S. P., Dhiwar, P. S., Patel, S., & Giles, D. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200721104431 · Cited by 41 · see citing works

HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability

Elwaie, T. A., Abbas, S. E.-S., Aly, E. I., George, R. F., Ali, H. E. A., Kraiouchkine, N., Abdelwahed, K. S., Fandy, T. E., Sayed, K. A. E., Elmageed, Z. Y. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01647 · Cited by 41 · see citing works

Bestowal of Quinazoline Scaffold in Anticancer Drug Discovery

Das, R., Mehta, D. K., & Dhanawat, M. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200627205321 · Cited by 36 · see citing works

Discovery of N -(1-(3-fluorobenzoyl)-1 H -indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B

Elkamhawy, A., Paik, S., Kim, H. J., Park, J. H., Londhe, A. M., Lee, K., Pae, A. N., Park, K. D., & Roh, E. J. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1800666 · Cited by 35 · see citing works

Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview

Das, D., Wang, J., & Hong, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100166 · Cited by 34 · see citing works

A novel three-component reaction between isocyanides, alcohols or thiols and elemental sulfur: a mild, catalyst-free approach towards O-thiocarbamates and dithiocarbamates

Németh, A. G., Keserű, G. M., & Ábrányi‐Balogh, P. (2019) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.15.155 · Cited by 29 · see citing works

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases

Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00964 · Cited by 26 · see citing works

Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model

Bollenbach, M., Lugnier, C., Kremer, M., Salvat, É., Megat, S., Bihel, F. J. ‐., Bourguignon, J., Barrot, M., & Schmitt, M. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.026 · Cited by 25 · see citing works

Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines

Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 24 · see citing works

Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design

Zhang, Z., Wang, Y., Chen, X., Song, X., Tu, Z., Chen, Y., Zhang, Z., & Ding, K. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116457 · Cited by 24 · see citing works

Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer

Wang, X., Qin, Z., Qiu, W., Xu, K., Bai, Y., Zeng, B., Ma, Y., Yang, S., Shi, Y. Y., & Fan, Y. L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116711 · Cited by 24 · see citing works

CuBr‐catalysed one‐pot multicomponent synthesis of 3‐substituted 2‐thioxo‐2,3‐dihydroquinazolin‐4(1H)‐one derivatives

Sayahi, M. H., Saghanezhad, S. J., Bahadorikhalili, S., & Mahdavi, M. R. (2018) · Applied Organometallic Chemistry · doi:10.1002/aoc.4635 · Cited by 24 · see citing works

Targeting Her2-insYVMA with Covalent InhibitorsA Focused Compound Screening and Structure-Based Design Approach

Lategahn, J., Hardick, J., Grabe, T., Niggenaber, J., Jeyakumar, K., Keul, M., Tumbrink, H. L., Becker, C., Hodson, L. E., Kirschner, T., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00870 · Cited by 22 · see citing works

Covalent Kinase Inhibitors: An Overview

Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 22 · see citing works

Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update

Roskoski, R. J. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107805 · Cited by 21 · see citing works

Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment

Wang, C., Wang, X., Huang, Z. L., Wang, T., Nie, Y., Yang, S., Xiang, R., & Fan, Y. L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114381 · Cited by 20 · see citing works

Recent advances in the design of small molecular drugs with acrylamides covalent warheads

Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 19 · see citing works

Deciphering quinazoline derivatives’ interactions with EGFR: a computational quest for advanced cancer therapy through 3D-QSAR, virtual screening, and MD simulations

Anwar, S., Alanazi, J., Ahemad, N., Raza, S., Chohan, T. A., & Saleem, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399372 · Cited by 18 · see citing works

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening

Elkamhawy, A., Ammar, U. M., Paik, S., Abdellattif, M. H., Elsherbeny, M. H., Lee, K., & Roh, E. J. (2021) · Molecules · doi:10.3390/molecules26175324 · Cited by 16 · see citing works

Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity

Imaizumi, T., Akaiwa, M., Abe, T., Nigawara, T., Koike, T., Satake, Y., Watanabe, K., Kaneko, O., Amano, Y., Mori, K., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116949 · Cited by 14 · see citing works

Acceptorless Dehydrogenative Cyclization of o ‐Aminobenzylamines and Aldehydes to Quinazolines in Water Catalyzed by a Water‐Soluble Metal‐Ligand Bifunctional Catalyst

Fan, H., Zhang, W., Zhao, W., & Li, F. (2017) · ChemistrySelect · doi:10.1002/slct.201700871 · Cited by 14 · see citing works

Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment

Wang, C., Wang, X., Wang, X., Tian, B., Zhang, S., Wang, T., Ma, Y., & Fan, Y. L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107004 · Cited by 12 · see citing works

Small-Molecule Anti-Cancer Drugs From 2016 to 2020: Synthesis and Clinical Application

Wang, L., Li, R., Song, C., Chen, Y., Long, H., & Yang, L. (2021) · Natural Product Communications · doi:10.1177/1934578x211040326 · Cited by 11 · see citing works

The relationship between EGFR mutation status and clinic-pathologic features in pulmonary adenocarcinoma

Deng, H., Liu, J., Duan, X., & Liu, Y. (2017) · Pathology - Research and Practice · doi:10.1016/j.prp.2017.09.008 · Cited by 9 · see citing works

Facile Non‐Transition Metal‐Catalyzed Synthesis of 2‐Thioxo‐2,3‐dihydroquinazolin‐4(1 H )‐one Derivatives via One‐Pot Multicomponent Reactions

Bahadorikhalili, S., Rahimzadeh, G., Kianmehr, E., Ansari, S., Hamedifar, H., & Mahdavi, M. (2019) · ChemistrySelect · doi:10.1002/slct.201802861 · Cited by 9 · see citing works

A multifaceted approach for the development of novel Hantzsch 1,4-dihydropyridines as anticancer agents: Rational design, parallel synthesis, analysis, cytotoxicity and EGFR/HER2 inhibition studies

Sruthi, A. S. V. L., Faizan, S., Vikram, P. R. H., Veena, N. G., Susil, A., Harindranath, H., Kumar, S. V., Shivaraju, V. K., & Kumar, B. R. P. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101413 · Cited by 8 · see citing works

Design, synthesis and biological activities of N-(furan-2-ylmethyl)-1H-indole-3-carboxamide derivatives as epidemal growth factor receptor inhibitors and anticancer agents

Zhang, L., Deng, X., Wu, J., Meng, G., Liu, C.-C., Chen, G., Zhao, Q., & Hu, C. (2017) · Chemical Research in Chinese Universities · doi:10.1007/s40242-017-7041-x · Cited by 6 · see citing works

Free Radical Scavenging and Cytotoxic Activities of Substituted Pyrimidines

Ain, Q. U. (2020) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2020.16.555940 · Cited by 4 · see citing works

Identification of the HECT domain binding of indole-3-carbinol (I3C) derivatives for breast cancer therapy

Zheng, W., Shi, Z., Zhang, X., Wu, W., Yuan, Z., Zhao, L., Li, Q., Qiu, Z., Zhang, C., Chu, B., et al. (2023) · Phytochemistry Letters · doi:10.1016/j.phytol.2023.01.002 · Cited by 3 · see citing works

Resistance to HER2-Targeted Therapy

Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 3 · see citing works

The peptide-Au clusters inhibit EGFR exon 19 deletion mutant non-small cell lung cancer

Zhao, W., Huo, W., Dang, H., Du, Z., Yuan, Q., Cao, K., & Gao, X. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102744 · Cited by 2 · see citing works

Thermal Stability and Utility of Dienes as Protecting Groups for Acrylamides

Hooper, A. R., & Burns, A. S. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00075 · Cited by 2 · see citing works

Topomer-CoMFA proposed as a tool to construct dual EGFR/HER-2 models

de Paula, H., de Angelo, R. M., & Honório, K. M. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04852-8 · Cited by 2 · see citing works

Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer

Gu, X. Q., Zhang, Z., Jiao, M.-R., Peng, X., Li, J., & Zhang, Q. (2021) · Pharmaceutical Fronts · doi:10.1055/s-0041-1731081 · Cited by 2 · see citing works

Catalyst‐Free One‐Pot Multi‐Component Synthesis of 2‐Substituted Quinazolin‐4‐carboxamides from 2‐Aminophenyl‐2‐oxoacetamides, Aldehydes, and Ammonium Acetate

Shim, S., Park, H., Mishra, N. K., Kim, I. S., Lee, J. K., Lee, K., Jalani, H. B., & Choi, Y. (2021) · ChemistrySelect · doi:10.1002/slct.202100534 · Cited by 2 · see citing works

Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction

Fischer, F., Temml, V., & Schuster, D. (2025) · Molecules · doi:10.3390/molecules30102183 · Cited by 1 · see citing works

Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors

Patel, H., Pawara, R. H., & Surana, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102661-8.00003-2

Antineoplastic and Immunomodulating Agents (L)

Kleemann, A. (2022) · Ullmann's Encyclopedia of Industrial Chemistry · doi:10.1002/14356007.a05_001.pub4

In-Silico Evaluation, Chemical Reactivity, and Covalent Docking Study of Various Quinazolines and Pyridopyrimidines as Inhibitors for the Epidermal Growth Factor Receptor

Khelfaoui, H., Harkati, D., Saleh, B. A., Hewitt, N. L., Alnajjar, R. A., & El-Hiti, G. A.-R. (2023) · Polycyclic aromatic compounds · doi:10.1080/10406638.2023.2237628

CẢI TIẾN QUY TRÌNH TỔNG HỢP 7-CLORO-6-NITROQUINAZOLIN- 4(3H)-ON LÀM TRUNG GIAN TRONG ĐIỀU CHẾ CÁC THUỐC ỨC CHẾ EGFR TYROSINE KINASE THẾ HỆ 2

Lương, T. T., Vũ, T. N. T., Nguyễn, H., Nguyễn, H. B., Nguyễn, V. G., Đào, N. S. H., Nguyễn, V. H., Trương, T. H. H., Bùi, T. T. C., & Nguyễn, T. N. (2025) · Tạp chí Y Dược học Cần Thơ · doi:10.58490/ctump.2025i83.3294

Design, synthesis, and evaluation of novel quinazoline derivatives as potent EGFR inhibitors: In silico and in vitro approaches

Saadh, M. J., Saeed, T. N., Alfarttoosi, K. H., Kakkad, A., Ganesan, S., Shankhyan, A., Sunitha, S., Aminov, Z., Taher, W. M., Alwan, M., et al. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111204

Discovery of new acetylcholinesterase inhibitors derived from quinazolinones: synthesis, in vitro, and molecular docking study

Danova, A., Christy, A. C., Musthapa, I., Kurniadewi, F., Chavasiri, W., Mujahidin, D., Roswanda, R., & Hermawati, E. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e162676

BindingDB Entry 50012678: HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and

BindingDB (2022) · UC San Diego · doi:10.7270/q2mw2mt4

BindingDB Entry 50018558: Targeting Gatekeeper Mutations for Kinase Drug Discovery.

BindingDB (2024) · UC San Diego · doi:10.7270/q25t3qqp

BindingDB Entry 50011340: Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.

BindingDB (2022) · UC San Diego · doi:10.7270/q2vq368t

BindingDB Entry 50008406: Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR

BindingDB (2021) · UC San Diego · doi:10.7270/q2t72mvw

BindingDB Entry 50015923: Discovery and biological evaluation of 1-{2,7-diazaspiro[3.5]nonan-2-yl}prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability and anti-tumor activity.

BindingDB (2023) · UC San Diego · doi:10.7270/q23t9n5b

BindingDB Entry 50001945: Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

BindingDB (2020) · UC San Diego · doi:10.7270/q25x2cjz

BindingDB Entry 50015538: Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.

BindingDB (2023) · UC San Diego · doi:10.7270/q2jh3r3b

BindingDB Entry 50022193: Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer.

BindingDB (2025) · UC San Diego · doi:10.7270/q26q22zv

BindingDB Entry 50007606: Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.

BindingDB (2021) · UC San Diego · doi:10.7270/q2474f5d

BindingDB Entry 50019133: An overview of quinazolines: Pharmacological significance and recent developments.

BindingDB (2024) · UC San Diego · doi:10.7270/q2c82fkj

BindingDB Entry 50013133: Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR

BindingDB (2022) · UC San Diego · doi:10.7270/q2w099nb

BindingDB Entry 50009091: Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.

BindingDB (2021) · UC San Diego · doi:10.7270/q2c250w8

BindingDB Entry 50015722: Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

BindingDB (2023) · UC San Diego · doi:10.7270/q2hq43wx

BindingDB Entry 50022952: Recent advances in the design of small molecular drugs with acrylamides covalent warheads.

BindingDB (2026) · UC San Diego · doi:10.7270/q2rv0tkm

BindingDB Entry 50022416: A review: FDA-approved fluorine-containing small molecules from 2015 to 2022.

BindingDB (2025) · UC San Diego · doi:10.7270/q2wd4580

BindingDB Entry 50016270: Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.

BindingDB (2023) · UC San Diego · doi:10.7270/q2z323nv

Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors

Klutchko, S. R., Zhou, H., Winters, R. T., Tran, T. P., Bridges, A. J., Althaus, I. W., Amato, D. M., Elliott, W. L., Ellis, P. A., Meade, M. A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050936o · Cited by 81 · see citing works

5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase

Ballard, P. G., Bradbury, R. H., Hennequin, L. F., Hickinson, D. M., Johnson, P. D., Kettle, J. G., Klinowska, T. C. M., Morgentin, R., Ogilvie, D., & Olivier, A. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.068 · Cited by 33 · see citing works

The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor

Reed, J. E., & Smaill, J. B. (2016) · ACS symposium series · doi:10.1021/bk-2016-1239.ch008 · Cited by 8 · see citing works

A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

Barlaam, B. C., Ballard, P. G., Bradbury, R. H., Ducray, R., Germain, H., Hickinson, D. M., Hudson, K., Kettle, J. G., Klinowska, T. C. M., Magnien, F., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.052 · Cited by 18 · see citing works

Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

Smaill, J. B., Showalter, H. D. H., Zhou, H., Bridges, A. J., McNamara, D. J., Fry, D. W., Nelson, J. M., Sherwood, V., Vincent, P. W., Roberts, B. J., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000372i · Cited by 89 · see citing works